SERUM ANALYSIS OF AMYLOID BETA-PROTEIN ^Sub 1-40^ IN HEALTHY SUBJECTS, AUTISTIC CHILDREN AND ALZHEIMER'S PATIENTS

By Singh, Vijendra K. | The Journal of Special Education and Rehabilitation, January 1, 2008 | Go to article overview

SERUM ANALYSIS OF AMYLOID BETA-PROTEIN ^Sub 1-40^ IN HEALTHY SUBJECTS, AUTISTIC CHILDREN AND ALZHEIMER'S PATIENTS


Singh, Vijendra K., The Journal of Special Education and Rehabilitation


Abstract

Amyloid beta-protein^sub 1-40^ (AP40) is a low molecular weight peptide produced throughout life during normal cell metabolism and neurodegenerative diseases. Owing to its neurotrophic and neurotoxic effects, the present study was conducted to evaluate serum levels of AP40 in healthy subjects, autistic children and Alzheimer's disease patients. Serum AP40 was measured by enzyme-linked immunosorbent assay (ELISA). AP40 was significantly higher in normal children compared to normal older controls, in normal children compared to autistic children, and in autistic children compared to Alzheimer's patients (p value was less than 0.05 for all groups). This finding suggests an age-related decline of serum AP40 in normal aging, as well as in autism and Alzheimer's disease. This decline may result from abnormal processing of amyloid beta-protein precursor (APP) during normal aging and age-related diseases such as autism in children and Alzheimer's disease in elderly. Possible explanations for this decline may include age-related increased interactions of AP40 with cytoskeletal proteins for brain tissue deposition, increased serine proteases for APP metabolism or hyperimmune reaction (antibodies to AP40) for removal of circulating AP40. To conclude, the AP40 metabolism declines with normal aging and in addition to its role in Alzheimer's disease this protein might also be a contributing factor in autism.

Key Words: Autism; Amyloid-beta protein, Alzheimer's disease; Aging, Neuropathology

(ProQuest: ... denotes non-US-ASCII text omitted.)

Introduction

Accumulation of AP40 occurs in the brain during normal aging but its amount is increased in the brain of patients with Alzheimer's disease (1). In addition to brain, AP40 has been localized outside the brain in skin fibroblasts and biological fluids, including the blood serum. AP40 is well known to exhibit both neurotrophic and neurotoxic effects (2-4), including neurogenic action on neural stem cells (5). Considering these properties, we hypothesized that AP40 might play a pathogenic role in autism.

Autism is an early-onset disorder of the developing central nervous system (CNS), manifesting both neurological and behavioral impairments. The disorder causes severe deficits of higher mental functions such as social interaction, language, cognition, communication, and imagination. Autism is the fastest-growing developmental disability today. The disorder affects millions of people worldwide, but very little is known about the etiology and pathogenesis of the disorder. Current theories include genetic factors, immune factors, environmental factors and yet other unidentified factors. The evidence is rapidly accumulating to support "autoimmune hypothesis" in autism (6-10). Autoimmunity in autistic children is shown by several autoimmune factors: brain-specific autoantibodies, impaired lymphocyte functions, abnormal cytokine regulation, viral association, linkage of certain immunogenetic factors, and response to immune modulation therapy (6-10).

The present study describes results of laboratory analysis of serum AP40, which was found to decline during normal aging, autistic children and Alzheimer's patients. Preliminary findings of this study were presented elsewhere (11).

Human Subjects and Methods

The study included 53 normal children (age 3-13 yrs), 9 normal adults (age 25-40 yrs), 9 normal aged controls (age 50-80 yrs), 53 autistic children (age 4-12 yrs) and 21 Alzheimer's disease patients (age 60-82 yrs). The clinical diagnosis of autism was made essentially according to the standard DSM-IV criteria of the American Association of Psychiatrists, Washington, DC. Neurologists made the clinical diagnosis of Alzheimer's disease (AD) according to the NINCDS-ADRDA criteria, which also included a 'Mini-Mental State' examination and a two-year downward course of the disease progression. The IRB of Utah State University and the University of Michigan reviewed and approved our research protocol involving the use of human blood samples (6-8). …

The rest of this article is only available to active members of Questia

Sign up now for a free, 1-day trial and receive full access to:

  • Questia's entire collection
  • Automatic bibliography creation
  • More helpful research tools like notes, citations, and highlights
  • Ad-free environment

Already a member? Log in now.

Notes for this article

Add a new note
If you are trying to select text to create highlights or citations, remember that you must now click or tap on the first word, and then click or tap on the last word.
One moment ...
Default project is now your active project.
Project items

Items saved from this article

This article has been saved
Highlights (0)
Some of your highlights are legacy items.

Highlights saved before July 30, 2012 will not be displayed on their respective source pages.

You can easily re-create the highlights by opening the book page or article, selecting the text, and clicking “Highlight.”

Citations (0)
Some of your citations are legacy items.

Any citation created before July 30, 2012 will labeled as a “Cited page.” New citations will be saved as cited passages, pages or articles.

We also added the ability to view new citations from your projects or the book or article where you created them.

Notes (0)
Bookmarks (0)

You have no saved items from this article

Project items include:
  • Saved book/article
  • Highlights
  • Quotes/citations
  • Notes
  • Bookmarks
Notes
Cite this article

Cited article

Style
Citations are available only to our active members.
Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

(Einhorn, 1992, p. 25)

(Einhorn 25)

1

1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

Cited article

SERUM ANALYSIS OF AMYLOID BETA-PROTEIN ^Sub 1-40^ IN HEALTHY SUBJECTS, AUTISTIC CHILDREN AND ALZHEIMER'S PATIENTS
Settings

Settings

Typeface
Text size Smaller Larger Reset View mode
Search within

Search within this article

Look up

Look up a word

  • Dictionary
  • Thesaurus
Please submit a word or phrase above.
Print this page

Print this page

Why can't I print more than one page at a time?

Help
Full screen

matching results for page

    Questia reader help

    How to highlight and cite specific passages

    1. Click or tap the first word you want to select.
    2. Click or tap the last word you want to select, and you’ll see everything in between get selected.
    3. You’ll then get a menu of options like creating a highlight or a citation from that passage of text.

    OK, got it!

    Cited passage

    Style
    Citations are available only to our active members.
    Sign up now to cite pages or passages in MLA, APA and Chicago citation styles.

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn, 1992, p. 25).

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences." (Einhorn 25)

    "Portraying himself as an honest, ordinary person helped Lincoln identify with his audiences."1

    1. Lois J. Einhorn, Abraham Lincoln, the Orator: Penetrating the Lincoln Legend (Westport, CT: Greenwood Press, 1992), 25, http://www.questia.com/read/27419298.

    Cited passage

    Thanks for trying Questia!

    Please continue trying out our research tools, but please note, full functionality is available only to our active members.

    Your work will be lost once you leave this Web page.

    For full access in an ad-free environment, sign up now for a FREE, 1-day trial.

    Already a member? Log in now.